[ RECIPIENT ENTITY RECORD ]

GSK Aiolos Platform

VERIFIED NODE ID: 002117 · gsk-aiolos-platform
R TARGET NODE — CAPITAL RECIPIENT
GSK Aiolos Platform
SPV United Kingdom
Recipient Type
SPV
Primary Jurisdiction
United Kingdom
Registration Status
ACTIVE
Entity Intelligence [ R ]
Legal Name GSK Aiolos Platform
Entity Type SPV
Jurisdiction United Kingdom
Recipient Intelligence Summary

GSK Aiolos Platform represents the leading respiratory medicine division focused on developing long-acting therapies for chronic asthma. The project includes advanced antibody technology for specialty drug development. It was a significant recipient of institutional healthcare capital through a targeted biotech takeover.

Capital Influx Log (Transactions)
Date Type Amount
23 May 2026 EQUITY $140.0M